January 22, 2014
ALPCO's New FDA Cleared 25-OH Vitamin D Total ELISA Provides Option for Hospitals and Smaller Clinical Labs to Bring Affordable Testing In-House
ALPCO announced in a press release on January 22, 2014 that their test portfolio for clinical and hospital laboratory customers has expanded to include a new FDA 510(k) cleared 25-OH Vitamin D Total ELISA.
The growth in 25-OH Vitamin D testing has been a challenge for clinical and hospital laboratories who are at a crossroads in determining whether it is more economically viable to manage testing in-house or to continue to send samples out to large commercial reference laboratories. The new FDA 510(k) cleared 25-OH Vitamin D Total ELISA from ALPCO affords these labs the option to test Vitamin D internally without the capital expenditure burden of expensive LC-MS/MS or closed automated systems.
A key attribute of the 25-OH Vitamin D Total ELISA is the unique in-well sample pretreatment for release of Vitamin D from endogenous binding proteins, allowing for a streamlined workflow compared to other commercially available 25-OH Vitamin D Total ELISAs. ALPCO’s 25-OH Vitamin D Total ELISA demonstrates excellent correlation with LC-MS/MS, and can be run either manually or on an open ELISA platform.